Innate Pharma has released the safety and efficacy results of a Phase I trial testing its antibody candidate IPH4102 in tumors with high unmet clinical need.
Innate Pharma is a biotech company in Marseille, France, developing antibody therapies for multiple cancer indications with big partners like Bristol-Myers Squibb and AstraZeneca. The company has just announced positive Phase I results from its candidate IPH4102 in patients with relapsed refractory cutaneous T-cell lymphomas (CTCL) that do not respond to standard treatments.
In addition to proving it was well tolerated, the candidate achieved an overall response rate (ORR) of 41.7%. In patients with Sézary syndrome, a subtype with high unmet clinical need, the ORR was 47.4%. “We are thrilled by these results, given that the trial included patients who had received all available treatment options,” said Pierre Dodion, CMO of Innate Pharma, in a statement.
IPH4102, which has been granted orphan drug status by the EMA, is a first-in-class anti-KIR3DL2 antibody that triggers immune cells to kill tumoral cells. KIR3DL2 is an inhibitory receptor expressed by tumoral cells in 65% of CTCL patients across all subtypes, and the percentage can go up to 85% in certain aggressive subtypes such as the Sézary syndrome.
The next part trial will expand to patients with Sézary syndrome and mycosis fungoides. In that second indication, Innate Pharma will have to compete with Actelion’s Ledaga, which was recently approved for this rare form of cancer. Other competitors for the French biotech in the broader CTCL space are 4SC and ArgenX.
IPH4102 is wholly owned by Innate Pharma, unlike the biotech’s two leading compounds. Monalizumab, co-developed in partnership with AstraZeneca, could bring the French biotech up to a massive €1.2B ($1.28B). Lirilumab is licensed to Bristol-Myers Squibb and being tested in combination with other cancer drugs in several indications. However, a Phase II trial with lirilumab in acute myeloid leukemia recently failed, raising doubts about its efficacy and driving the company’s stock down by 25%.
Images via Spectral-Design /Shutterstock; Innate Pharma